TS-005534 — This innovative serum replacement is a new chemically defined composition formulated for culturing cells. In specific, this serum is the first of its kind to optimized for mouse CD4+ and CD8+ T cells, allowing reproducible ex vivo expansion and functional activation without animal derived serums, leading to a controllability and consistency for preclinical research and immune cell studies. The serum replacement also supports human T cell viability and proliferation, allowing cross-species applicability and translational potential.

TS-000738 — In all living cells, extracellular vesicles (EVs) are naturally produced. Drs. Kevin Cassady and Uksha Saini have developed a streamlined approach to utilize these EVs to deliver biologics and clinical drug treatments that permit repeated treatments without the possibility of limiting therapeutic delivery due to the natural immune response. This method produces an immune inert drug delivery system that, unless the EVs are designed to encode immunostimulatory molecules, should not invoke an immune response. Our preliminary studies show that we can load extracellular vesicles (EVs) with a therapeutic payload of our choice. Retroviruses co­opt and use much of the same pathways involved in cellular EV production for virus exit of the infected cell. We therefore hypothesized that Lentiviruses (a non-replicating retrovirus commonly used in the lab for gene expression) would provide a modifiable platform to generate therapeutic gene products that that would be preferentially transported and packaged into cellular EVs. This platform could then be modified and developed as a potential therapeutic delivery platform.